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Abstract
Background: Expansion of beta cells from the limited number of adult human islet donors is an attractive prospect for
increasing cell availability for cell therapy of diabetes. However, attempts at expanding human islet cells in tissue culture
result in loss of beta-cell phenotype. Using a lineage-tracing approach we provided evidence for massive proliferation of
beta-cell-derived (BCD) cells within these cultures. Expansion involves dedifferentiation resembling epithelial-mesenchymal
transition (EMT). Epigenetic analyses indicate that key beta-cell genes maintain open chromatin structure in expanded BCD
cells, although they are not transcribed. Here we investigated whether BCD cells can be redifferentiated into beta-like cells.
Methodology/Principal Finding: Redifferentiation conditions were screened by following activation of an insulin-DsRed2
reporter gene. Redifferentiated cells were characterized for gene expression, insulin content and secretion assays, and
presence of secretory vesicles by electron microscopy. BCD cells were induced to redifferentiate by a combination of soluble
factors. The redifferentiated cells expressed beta-cell genes, stored insulin in typical secretory vesicles, and released it in
response to glucose. The redifferentiation process involved mesenchymal-epithelial transition, as judged by changes in
gene expression. Moreover, inhibition of the EMT effector SLUG (SNAI2) using shRNA resulted in stimulation of
redifferentiation. Lineage-traced cells also gave rise at a low rate to cells expressing other islet hormones, suggesting
transition of BCD cells through an islet progenitor-like stage during redifferentiation.
Conclusions/Significance: These findings demonstrate for the first time that expanded dedifferentiated beta cells can be
induced to redifferentiate in culture. The findings suggest that ex-vivo expansion of adult human islet cells is a promising
approach for generation of insulin-producing cells for transplantation, as well as basic research, toxicology studies, and drug
screening.
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Introduction
Beta-cell replacement is a promising approach for the cure of
type 1 diabetes, however, its application is limited by the shortage
of pancreas donors. In-vitro expansion of human cadaveric islet
beta cells represents an attractive strategy for generation of
abundant beta-like cells [1–5]. Human beta cells manifest a very
low proliferation capacity in vivo [6–8], and intact isolated islets
cultured in suspension do not proliferate, although they remain
functional for months [9]. When islets are allowed to attach,
limited replication of beta cells can be induced by growth factors
or extracellular matrix components [10] before the beta-cell
phenotype is lost. To determine the fate of cultured beta cells we
established a lineage tracing system based on a dual lentiviral
vector system [11]. This system provided evidence for survival and
dedifferentiation of adult human beta cells, and significant
replication of beta-cell-derived (BCD) cells. The phenotypic
changes in BCD cells resembled epithelial-mesenchymal transition
(EMT) [12], as originally suggested by Gershengorn et al. [2].
EMT likely results from islet cell dissociation and exposure to
culture conditions, and may be involved in triggering changes in
gene expression, leading to beta-cell dedifferentiation and
replication. Epigenetic analyses of BCD cells indicated that key
beta-cell genes maintained a partially open chromatin structure,
although they were not transcribed [13]. This epigenetic memory
was maintained even following BCD cell reprogramming into
induced pluripotent stem (iPS) cells [13]. We hypothesized that
this epigenetic memory rendered BCD cells attractive candidates
for generation of insulin-producing cells by redifferentiation. BCD
cell expansion could generate sufficient cells for human beta-cell
replacement, if the lost cell phenotype can be restored. Here we
report that BCD cells can be preferentially redifferentiated by a
combination of soluble factors in serum-free medium (SFM). The
redifferentiated cells re-express beta-cell genes, process and store
insulin in typical secretory vesicles, and release it in response to
glucose. The redifferentiation process involves mesenchymal-
epithelial transition (MET) and activation of genes expressed in
islet progenitor cells. These findings suggest that ex-vivo expansion
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25566of adult human islet beta cell is a promising approach for
generation of insulin-producing cells for transplantation.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The Institutional Review Boards of
the following medical centers, which provided human islets, each
provided approval for the collection of samples and subsequent
analysis: University of Geneva School of Medicine; San Raffaele
Hospital, Milan; Faculty of Medicine, Lille 2 University;
Massachusetts General Hospital; Washington University; Univer-
sity of Pittsburgh; Scharp/Lacy Institute; University of Minnesota.
All donors provided written informed consent for the collection of
all samples and subsequent analysis.
Cell culture
Islets from individual donors (Table 1) were dissociated into
single cells, and beta cells were labeled and expanded as previously
described [4,11,12,14]. For differentiation cells were trypsinized
and seeded at 3.2610
4/cm
2 in ultra-low attachment plates
(Corning). SFM consisted of CMRL 1066 containing 5.6 mM
D-glucose and supplemented with 1% BSA fraction V (Sigma),
ITS (Gibco-Invitrogen), penicillin (50 units/ml), and streptomycin
(50 mg/ml). Redifferentiation Cocktail (RC) treatment consisted of
6 days in SFM supplemented with 25 mM D-glucose, N2 and B27
supplements (Stem Cell Technologies), 10 mM nicotinamide
(Sigma), 8 nM exendin-4 (Acris), and 8 nM activin A (Peprotech),
followed by 2 days in the same medium lacking activin A and
containing a reduced glucose concentration (5.6 mM). Human
fibroblasts were maintained in DMEM containing 10% FCS
(Gibco), 100 U/ml penicillin, and 100 mg/ml streptomycin.
Human bone marrow-derived mesenchymal stem cells (BM-
MSC) were isolated and cultured as described [15].
Virus production and cell transduction
RIP-Cre/ER and pTrip–loxP-NEO-STOP-loxP-eGFP lentivi-
rus vectors have been described [12]. SLUG shRNAs (accession
numbers TRCN-15389, - 15388, - 15390, - 15391, -15392), and a
non-target shRNA, all cloned in the pLKO.1 lentiviral vector,
containing a puromycin-resistance gene, were obtained from the
RNAi Consortium (Sigma-Aldrich). Virus production, cell infec-
tion, and tamoxifen treatment were previously described. For
SLUG inhibition, transduced cells were selected for puromycin
resistance (1 mg/ml) for 3 days.
Cell sorting
Labeled cells were sorted using a FACS Aria sorter (Becton
Dickinson, San Jose, CA) as described [11,12].
Flow cytometry
Cells were dissociated with trypsin, resuspended in PBS
containing 2% FCS, and filtered through a cell strainer. Flow
cytometry was preformed on FACsort (BD Bioscience) using
FlowJo software (Tree Star). Final analysis was done using Cyflogic
software (Cyflogic). Untreated cells, and infected cells without
differentiation treatment, served as controls.
Cell proliferation and apoptosis analyses
Cells were incubated with 10 mM BrdU (Sigma) for 7 days,
starting one day following initiation of RC treatment. Apoptotic
cells was detected by TUNEL staining using the TACSNXL
Apoptosis Detection Kit (R&D Systems Inc., Minneapolis, MN).
qPCR analyses
Total RNA was extracted using RNAeasy Plus Micro Kit (Qiagen)
or Trizol (Sigma-Aldrich) and treated with DNA-Free
TM (Ambion).
cDNA was prepared using High Capacity cDNA RT Kit (Applied
Biosystems). qPCR was carried out in triplicates using TaqMan
Table 1. Donors of islets used in the study.
Donor No. Donor Sex Donor Age (y) Donor BMI Islet purity (%)
1 F 27 ND 95
2 F 63 39.3 80
3 F 66 29.4 83
4 M 50 37.0 92
5 F 34 22.5 80
6 M 42 22.5 70
7 F 24 30.9 90
8 M 57 34.3 75
9 M 69 30.4 85
10 M 45 31.6 ND
11 M 54 26.9 85
12 M 47 23.0 85
13 F 51 39.3 80
14 M ND 35.0 80
15 F 36 43.0 90
16 M 26 19.8 65
17 M 57 32.4 80
18 F 69 29.7 90
19 M 29 20.7 80
20 M 38 22.9 85
21 M 58 33.4 65
22 F 55 26.6 80
23 M 55 22.4 70
24 F 38 24.0 75
25 M 55 27.0 70
26 M 62 24.2 90
27 F 38 20.8 95
28 M 62 30.6 ND
29 F 44 21.5 85
30 M 40 29.0 95
31 F 47 33.2 70
32 F 50 42.3 85
33 M 21 33.8 85
34 M 62 31.8 99
35 M 44 24.7 99
36 M 27 19.0 85
37 M 55 22.4 70
38 F 38 24.0 75
39 F 62 27.1 95
40 M 59 23.0 85
41 M 22 19.8 80
42 M 39 27.4 98
Average±SD 47±14 28±68 3 ±9
doi:10.1371/journal.pone.0025566.t001
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Library Master Mix (Roche) in 7300 Real-timePCRSystem (Applied
Biosystems). Results were normalized to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) and/or human large ribosomal protein
(RPLPO) transcripts. Primer sequences are listed in Table 2. All
reactions were performed with annealing at 60uC for 40 cycles. For
undetectable transcripts, the cycle number was set to 40 for
comparisons.
DNA microarray analysis
Hybridization to Affymetrix GeneChip Human Gene 1.0 ST
Arrays, washing, and scanning were performed according to the
manufacturer (Affymetrix, Santa Clara, CA). Microarray analysis
was performed on CEL files using PartekH Genomics Suite TM
(Partek Inc., St. Louis, MO). Data were normalized with the multi-
average method [16]. Batch effect removal was applied for the
different samples, followed by one-way ANOVA. Clustering
analysis was performed by Partek Genomics Suite software with
Pearson’s dissimilarity correlation by average linkage methods. All
data is MIAME compliant. The raw data has been deposited in
the GEO database (accession number GSE30732).
Transmission electron microscopy
Cells were fixed in 2.5% glutaraldehyde (EMS) in PBS
overnight at 4uC and postfixed in 1% OsO4 (EMS) in PBS for
2 hours at 4uC. Dehydration was carried out in graded ethanol
solutions, followed by embedding in Glycid ether. Thin sections
were mounted on Formvar/Carbon coated grids and examined in
Jeol 1200EX transmission electron microscope. Images were
captured using SIS Megaview III camera and iTEM imaging
platform (Olympus).
Immunofluorescence analyses
Cells were trypsinzed, spotted on slides using a Shandon
Cytospin4 centrifuge (Thermo Scientific), and fixed for 15 min at
RT in 4% paraformaldehyde (PFA). Paraffin sections were
rehydrated, and antigen retrieval was preformed before staining.
For BrdU staining slides were incubated in 1.5 M HCl for 20 min,
followed by 0.1 M sodium borate (pH 8,5) for 10 min at RT and 3
washes in PBS. All samples were blocked for .10 min in blocking
buffer (1% BSA, 5% fetal goat serum, and 0.2% saponin). Primary
antibodies (Table 3) were diluted in blocking buffer, and samples
were incubated for either 1 hour at RT or overnight at 4uC. Slides
were washed in PBST and incubated for 40 min with secondary
Table 2. Primer sequences.
Gene Sense primer Antisense primer
INS Taqman probe Hs 00355773 m1 Taqman probe Hs 00355773 m1
agaagaggccatcaagcaga caggtgttggttcacaaagg
PDX1 Taqman probe Hs_00426216_m1 Taqman probe Hs_00426216_m1
aagctcacgcgtggaaag gccgtgagatgtacttgttgaa
FOXA2 Taqman probe Hs_00232764_m1 Taqman probe Hs_00232764_m1
MAFA Taqman probe Hs01651425_s1 Taqman probe Hs01651425_s1
agcgagaagtgccaactcc ttgtacaggtcccgctcttt
GCG Taqman probe Hs01031536_m1 Taqman probe Hs01031536_m1
gtacaaggcagctggcaac tgggaagctgagaatgatctg
SST Taqman probe Hs00174949_m1 Taqman probe Hs00174949_m1
accccagactccgtcagttt acagcagctctgccaagaag
PPY Taqman probe Hs00237001_m1 Taqman probe Hs00237001_m1
tctagtgcccatttactctggac gcaggtggacaggagcag
AMY2A Taqman probe Hs00420710_g1 Taqman probe Hs00420710_g1
GAPDH
(h)
Taqman probe Hs_99999905_m1 Taqman probe Hs_99999905_m1
agccacatcgctcagacac gcccaatacgaccaaatcc
RPLPO Taqman probe Hs_99999902_m1 Taqman probe Hs_99999902_m1
tctacaaccctgaagtgcttgat caatctgcagacagacactgg
SUR1 agaccctcatgaaccgacag ggctctgtggcttttctctc
GCK gcagatgctggacgacag tcctgcagctggaactctg
KIR6.2 tgtgtcaccagcatccactc cacttggacctcaatggagaa
IAPP ttaccaaattgtagaggctttcg ccctgcctctatacactcactacc
PC1/3 tgatcccacaaacgagaaca tgtgattatttgcttgcatgg
HLXB9 Taqman probe Hs00907365_m1 Taqman probe Hs00907365_m1
NEUROD1 ctgctcaggacctactaacaacaa gtccagcttggaggacctt
NKX2-2 cgagggccttcagtactcc ggggacttggagcttgagt
NKX6-1 Taqman probe Hs00232355_m1 Taqman probe Hs00232355_m1
cgttggggatgacagagagt cgagtcctgcttcttcttgg
SNAI1 gctgcaggactctaatccaga atctccggaggtgggatg
SNAI2 tggttgcttcaaggacacat gttgcagtgagggcaagaa
NCAD ctccatgtgccggatagc cgatttcaccagaagcctctac
ECAD gccgagagctacacgttca gaccggtgcaatcttcaaa
SOX9 gtacccgcacttgcacaac tcgctctcgttcagaagtctc
PTF1A Taqman probe Hs_00603586_g1 Taqman probe Hs_00603586_g1
ARX gcaccacgttcaccagcta cagcctcatggccagttc
TCF2 Taqman probe Hs_00172123_m1 Taqman probe Hs_00172123_m1
TWIST aaggcatcactatggactttctct gccagtttgatcccagtatttt
PAX4 accccacctaaagcctgtct aggcaaagcagtcctgagtc
INSM1 cgctgtgttcatggtctagaaa catagagagcagagattggtaggc
KRT19 gccactactacacgaccatcc caaacttggttcggaagtcat
doi:10.1371/journal.pone.0025566.t002
Table 3. Antibodies used in immunofluorescence.
Antigen Antibody species Source Dilution
eGFP mouse
rabbit
Chemicon
Invitrogen
1:500
1:1000
C-peptide (human) mouse
rabbit
rat
Biodesign
Abcam
BCBC
1:200
1:100
1:1000
Glucagon mouse Sigma 1:2000
Somatostatin rabbit Dako 1:400
PPY rabbit Dako 1:200
Ki67 (human) rabbit Zymed 1:50
Vimentin mouse Calbiochem 1:50
PDX1 (human) rabbit Abcam 1:500
PCSK1 mouse Millipore 1:100
IAPP mouse Thermo Scientific 1:30
NKX2.2 mouse Hybridoma Bank 1:1000
NKX6.1 mouse Gift from P. Serup 1:1000
SOX9 rabbit Chemicon 1:200
FOXA2 rabbit Abcam 1:1000
BrdU mouse Chemicon 1:100
doi:10.1371/journal.pone.0025566.t003
Human Beta-Cell Expansion In Vitro
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e25566antibody conjugated to Alexa fluorophores (all from Invitrogen,
1:1000). Images were taken using a Leica SP5 confocal
microscope. Images of fluorescent living cells were taken with a
Nikon microscope equipped with a NIS Elements camera and
software. DNA was stained with DAPI (Sigma).
Immunoblotting
Total protein was extracted for 10 min in 1% NP40 containing
protease inhibitor cocktail. 20 mg protein were resolved on SDS-
PAGE gel and electroblotted onto Immobilon-P membrane
(Milipore), followed by incubation with rabbit anti-SOX9
(Chemicon, 1:200) or mouse anti-SLUG (Sigma, 1:50). Mouse
anti-actin (Sigma, 1:2000) or mouse anti-HSC70 (SantaCruz,
1:1000) was used to monitor loading. The bound antibody was
visualized with horseradish peroxidase-conjugated anti-IgG and
SuperSignal West Pico Chemiluminescent Substrate (Pierce).
Quantification was done using TINA software.
In situ hybridization
In situ hybridization analysis was performed on paraffin sections
of fetal pancreas and frozen sections of cell clusters as described
[17]. Cell clusters were fixed overnight in 4% PFA in PBS at 4uC,
incubated in 30% sucrose in PBS for 48 hours at 4uC, embedded
in OCT, and snap-frozen. Nine-mm sections were cut using a
CM3050S cryostat (Leica). A 557-bp fragment from the first
exon of NGN3 was amplified from human genomic DNA using the
primers 59agggagaagcagaaggaacaag39 and 59cctaagagc-
gagttggcactg39 and cloned into pGEM-T Easy Vector
system (Promega) . Sense/antisense probes were labeled
with digoxigenin using Sp6 or T7 polymerases, and
hybridized at 6 mg/ml overnight at 65uC. Slides were treated
with RNaseA, washed, blocked with 20% normal goat serum, and
incubated with sheep anti-digoxigenin Fab fragments conjugated
to alkaline phosphatase (1:2500, Roche) in blocking solution
overnight at 4uC. Slides were washed, and pigment was developed
using BM Purple (Roche).
Insulin content and secretion
Cell were preincubated for 1 hour in Krebs–Ringer buffer
(KRB), followed by incubation for 2 hours in KRB containing
0.5 mM 1-isobutyl 3-methylxanthine (IBMX) and 16.7 mM
glucose. C-peptide content was determined in acidic alcohol cell
extract. Human C-peptide levels were quantified using an
ultrasensitive ELISA kit (Mercodia; sensitivity 1.5 pmol/L; cross-
reactivity with insulin and proinsulin ,0.0006% and ,1.8%,
respectively). Human proinsulin levels were quantified using a
Proinsulin ELISA kit (Mercodia; sensitivity 0.5 pmol/L).
Statistical analysis
Significance was determined using two-tailed t-test and x
2 test.
To approach a normal distribution, logarithmic transformation
was preformed.
Results
Development of conditions for BCD cell redifferentiation
Incubation of expanded islet cells in SFM resulted in cell cluster
formation (Figure 1C) and a gradual increase in expression of beta-
cell transcripts during the 8-day incubation period (Figure 1A). To
screen for soluble factors which induce further differentiation, islet
cells were transduced with an insulin promoter-DsRed2 (RIP-
DsRed2) reporter lentivirus (Figure 1B). Loss of insulin promoter
activity during cell expansion, coupled with DsRed2 half-life of 4.5
days, resulted in marker disappearance (Figure 1C). Following
expansion, cells were transferred to SFM containing various
agents, and differentiation was evaluated in live cells by scoring
fluorescence reappearance. Based on preliminary screening of
individual agents and their combinations, a two-step differentia-
tion protocol termed Redifferentiation Cocktail (RC) was
optimized (see Materials and Methods). The factors included
activin A, exendin-4, nicotinamide, and high glucose concentra-
tions, which have been shown to promote beta-cell differentiation
[18–21]. N2, B27, and ITS, were included to prevent cell death in
the absence of serum. Glucose concentration was reduced in Step
2 to increase cell sensitivity to glucose-stimulated insulin release
[22]. This treatment resulted in cell cluster formation similar to
that seen with SFM alone (Figure 1C). However, the number of
DsRed2
+ cells was 6-fold higher in RC, compared with SFM
(Figure 1D).
Since islet cell cultures represent a mix of several cell types, the
observed differentiation could result from redifferentiation of BCD
cells, or de-novo differentiation of other cells. To determine the
origin of the newly-generated insulin-expressing cells we used our
inducible lineage tracing approach (Figure 1E). BCD cells were
labeled during the first days of culture with the RIP-Cre/ER and
pTrip–loxP-NEO-STOP-loxP-eGFP lentivirus vectors in the
presence of tamoxifen (TM) as previously described [12]. As seen
in Figure S1, Cre was specifically expressed in C-pep
+ cells.
Labeled islet cells at passages p4–6 were treated with SFM or RC,
and stained for human C-peptide and eGFP. Since the average
beta-cell labeling efficiency is 57.568.9% [11], the expected
incidence of C-pep/eGFP-double-positive cells in case of rediffer-
entiation should be close to this value, while de-novo differenti-
ation should result in 0% co-labeling in the absence of TM. The
actual incidence of double-positive cells found following SFM
treatment was 60616%, suggesting that redifferentiation was the
predominant mechanism (Figure 1F). Redifferentiation rate was
relatively low, with 4.763.0% of GFP
+ cells expressing C-peptide
(1–2% of total cells, compared with ,0.05% in cells incubated in
medium with serum). As observed with SFM alone, a large
fraction (38617%) of C-pep
+ cells co-stained for eGFP following
RC treatment, indicating that generation of C-pep
+ cells under
both conditions occurred primarily through redifferentiation of
BCD cells. Since the inducible labeling system was shown to have
a leakiness of 1.7% in the absence of TM [12], we can not exclude
a small contribution from non-BCD cells, transduced by both
vectors, to the eGFP
+ cell pool following differentiation treatments.
However, no increase in the fraction of eGFP
+ cells in the absence
of TM was noted following redifferentiation (data not shown).
Redifferentiation generates beta-like cells
Gene expression analysis of RC-treated cells at different time
points revealed a gradual increase in insulin expression (Figure 2A).
PDX1 and MAFA transcript levels similarly increased over time
(Figure 2A). To determine the kinetics of appearance of C-pep
+
cells, cells treated with RC were co-stained every other day for C-
peptide and PDX1 as markers of mature beta cells. As seen in
Figure 2B, the number of double-positive cells increased with time,
suggesting stochastic activation of the redifferentiation process,
rather than a synchronized initial priming followed by further
maturation. The differentiation rate peaked at 10.963.7% of total
cells on day 6, which is 5–10-fold higher than with SFM alone.
Given a fraction of ,45% BCD cells in the expanded cell
population [11], this efficiency represents ,25% redifferentiation
of BCD cells. Transcripts encoding HBLX9, NEUROD,
NKX2.2, and NKX6.1 were also strongly induced by RC
(Figure 2C). In addition, transcripts encoding KIR6.2, SUR1,
GCK, IAPP and PC1/3, were also significantly upregulated. Most
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PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e25566Figure 1. Development of conditions for islet cell differentiation, and demonstration that differentiation represents predominantly
BCD-cell redifferentiation. A: qPCR analysis of beta-cell gene expression in expanded islet cells at p6 incubated in SFM for the indicated number
of days. Values are mean6SD relative to untreated cells (d0) (n=3–4 donors) and normalized to human RPLPO. *p,0.05; **p,0.005. B–D: An assay
for screening islet cell differentiation conditions. Islet cells are transduced with a RIP-DsRed2 lentivirus (B) followed by testing different differentiation
conditions. C: No DsRed2 expression is observed in expanded cells at p5 (UTR, untreated cells), while cell transfer to SFM or RC results in insulin
promoter activation, which can be monitored in live cells by appearance of DsRed2 fluorescence. Bar=200 mm. D: Flow cytometry quantitation of
differentiation reveals that treatment with RC results in a 6-fold higher number of redifferentiated cells, compared with SFM. E: Schematic
representation of the viral vectors used for beta-cell labeling. F: Predictions for generation of insulin-expressing cells by different cell sources within
expanded islet cell populations. Initial cultures of islet cells consist of approximately half insulin-producing beta cells (purple filled circles) and half
non-beta cells (open circles). The labeling efficiency of beta cells is about 50% (green filled circles). Dedifferentiated islet cells are expanded and then
differentiated in SFM or RC, and the percent eGFP
+ cells among C-pep
+ cells is quantified. Redifferentiation of BCD cells is expected to result in ,50%
co-staining, given the eGFP labeling efficiency. De novo differentiation of insulin-expressing cells from non-BCD cells should result in no co-staining,
while occurrence of both mechanisms will result in a low percent of co-stained cells. The actual co-staining quantitation (bold arrow) revealed that
redifferentiation of BCD cells was the predominant source of insulin-expressing cells generated in both conditions. Percentages indicate fractiono f
eGFP
+ cells among C-pep
+ cells redifferentiated from expanded islet cells at p4–6 (based on counting .400 cells in each of 3 donors). A
representative micrograph is shown. DNA was stained blue with DAPI. Bar=10 mm.
doi:10.1371/journal.pone.0025566.g001
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NKX2.2 (65619%), NKX6.1 (5563%), IAPP (4769%) and
PC1/3 (68614%) (Figure 2D). Microarray analysis of gene
expression showed that RC induced a global phenotypic change
in expanded islet cells towards the phenotype of uncultured islet
cells, as revealed by hierarchical cluster analyses (Figure 2E).
However, the RC-treated samples were still noticeably different
from islet cells. This difference likely results from redifferentiation
of only part of BCD cells (,25%) achieved with RC, and from
analysis of mixed cell populations. Incubation of primary human
fibroblasts or BM-MSCs in RC did not result in detectable insulin
or PDX1 transcripts (data not shown), further supporting the
specific redifferentiation capacity of BCD cells.
To characterize the redifferentiated cells in greater detail,
expanded islet cells carrying the RIP-DsRed2 reporter gene were
incubated with RC. After 8 days cell clusters were dissociated, and
cells were FACS-sorted and characterized. Most DsRed2
+ cells
(.95%) stained for C-peptide. qPCR analysis of sorted DsRed2
+
cells detected levels of insulin transcripts averaging 50% of those
present in human islets (Figure 3A). Given the average islet purity
of 8369% (Table 1), and an average of 55% beta cells in human
islets [23], these islet preparations were expected to contain ,45%
insulin-positive cells; therefore insulin transcript levels in sorted
cells represent about 40% of those of normal human beta cells.
These levels represent a 13,300-fold increase over untreated cells
(Figure 3A). The levels of PDX1 and MAFA transcripts were
comparable to those in human islets (Figure 3A). In addition,
sorted redifferentiated cells stored 10% of the C-peptide levels
found in isolated human islets (Figure 3B). Most of the insulin
(,91%) was processed, as judged by human proinsulin-specific
ELISA (data not shown). Redifferentiated cells challenged with
16.7 mM glucose and 0.5 mM IBMX showed a 2-fold increase in
insulin release, compared with a 3-fold increase seen in islets
(Figure 3C). Typical insulin vesicles were detected by electron
microscopy, although their dense core appeared smaller, com-
pared with human islets (Figure 3D).
Expanded BCD cells maintain an open chromatin structure even
at the latest passage analyzed (p11) [13]. To test if late-passage cells
were still capable of redifferentiation they were treated with RC.
Islet cell cultures could be induced to efficiently redifferentiate even
Figure 2. Redifferentiation of BCD cells induced by soluble factors. A,B: Kinetics of induction of beta-cell genes in islet cells at p5 treated
with RC. A: qPCR analysis. Values are mean6SE relative to untreated cells (d0) (n=3–4 donors) and normalized to human RPLPO or GAPDH. *p,0.05;
**p,0.01. B: Immunofluorescence analysis of cells co-stained for C-peptide and PDX1. Values are mean6SE (logarithmic scale), based on counting
.500 cells from each of 3 donors at each time point. *p#0.05, relative to untreated cells (d0). A representative micrograph is shown. Bar=25 mm.
C,D: Analyses of beta-cell gene expression in islet cells at p5–7 treated with RC for 8d. C: qPCR analysis. Values are mean6SE (logarithmic scale)
relative to untreated cells (d0) (n=3–4 donors) and normalized to human RPLPO. *p,0.05; **p,0.005; ***p,0.0005. D: Immunofluorescence analysis
of cells co-stained for C-peptide and the indicated protein (in green). Bar=10 mm. The percentages indicate the fraction of cells positive for each
marker among C-peptide
+ cells. Data are mean6SD, based on counting .200 cells from each of 3 donors. E: Unsupervised clustering of gene
expression patterns detected in cDNA microarray analyses of uncultured islet cells from 4 donors, expanded islet cells at p5 from 4 donors (UTR), and
expanded islet cells at p5 from 3 donors treated with RC.
doi:10.1371/journal.pone.0025566.g002
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transcript levels in expanded islet cells declined with passaging.
Thus, although RC stimulated a similar fold increase in insulin
transcripts at early and late passages, transcript levels induced by
RC declined with passaging, when compared with those in islets.
One explanation for this observation could be that the epigenetic
memory in BCD cells is eroded with each cell division.
Redifferentiation is associated with MET
qPCR analysis revealed a significant upregulation of both
transcript and protein levels of the EMT effector SLUG (SNAI2)
during dedifferentiation, and a small but significant downregula-
tion during RC-induced redifferentiation (Figure 4A–C). In
contrast, no significant changes were noted in expression of
SNAIL (SNAI1) (Figure 4A,C) and TWIST (data not shown), two
other transcription factors involved in EMT. Transcripts for the
epithelial marker E-cadherin were significantly upregulated by
RC, while those encoding the mesenchymal marker N-cadherin
were significantly reduced (Figure 4D). In addition, while almost
all expanded islet cells stained positive for the mesenchymal
marker vimentin, upon redifferentiation C-pep
+ cells were
vimentin-negative, and the incidence of vimentin
+ cells in the cell
population decreased from 9862% to 8169% (Figure 4E). We
also found cells negative for both markers (Figure 4E, arrow),
which may represent cells that turned off vimentin expression but
have not yet activated insulin expression. These data indicate that
redifferentiated BCD cells transition from a mesenchymal to an
epithelial phenotype.
Staining of the redifferentiated cells for Ki67 did not detect
positive cells, suggesting that cell differentiation was accompanied
with growth arrest (data not shown). To further validate this
possibility, expanded islet cells were treated with RC in the
presence of BrdU. While control cells grown in expansion medium
readily incorporated BrdU, BrdU
+ cells were not detected in
cultures from 3 independent donors following RC treatment
(Figure 4F). In addition, only rare cells (0.960.6% based on
counting .500 cells in each of 3 donors) were apoptotic following
the full course of RC treatment, as determined by TUNEL assay
(data not shown).
To further explore the role of SLUG downregulation in BCD cell
redifferentiation, we employed two SLUG shRNAs to reduce
SLUG expression beyond the small reduction (3866%) induced by
RC. SLUG shRNA reduced SLUG protein levels by ,70%
(Figure 4G). When combined with RC, two different SLUG
shRNAs stimulated beta-cell transcript levels several fold, compared
with scrambled shRNA (Figure 4H), confirming the importance of
SLUG downregulation for BCD cell redifferentiation.
Lineage-traced cells give rise to cells expressing other
islet hormones
In addition to losing insulin expression, expanded islet cells are
devoid of cells expressing glucagon (GCG), somatostatin (SST),
and pancreatic polypeptide (PPY) (data not shown). RC treatment
resulted in appearance of immunostaining for each of these
hormones in ,2% of the treated cells (Figure 5A). Importantly, no
hormone co-expression was detected. To determine the origin of
these cells, eGFP-labeled expanded cells were treated with RC and
co-stained for eGFP and the four islet hormones. As seen in
Figure 5A, the majority (91.8%) of eGFP
+ cells which activated
islet hormone expression were C-pep
+. However, a small percent
expressed instead one of the other islet hormones, most notably
SST (6.5%). These analyses suggested that at least part of the cells
expressing islet hormones other than insulin were derived from
BCD cells, raising the possibility that redifferentiating BCD cells
transited through an islet progenitor-like stage. Analysis of
expanded islet cells for transcripts of pancreas- and islet-progenitor
cell transcription factors did not detect expression of PTF1A,
TCF2, and PAX4 (Ct .40), and showed low but detectable levels
of SOX9, FOXA2, and ARX transcripts (data not shown).
Following RC-induced redifferentiation, expression of some of
these factors was significantly induced. Thus, SOX9 transcripts
were upregulated 4-fold (Figure 5B), and .20% of the cells
became SOX9
+ within 2 days of RC treatment (Figure 5C). In
addition, FOXA2, PAX4, and ARX were also significantly
upregulated during this treatment (Figure S3). Cells co-expressing
SOX9 and vimentin could be detected, however SOX9 and C-
peptide expression was mutually exclusive (Figure 5D), suggesting
Figure 3. Insulin production and secretion in sorted rediffer-
entiated BCD cells. Expanded islet cells (p6–7) were transduced with
RIP-DsRed2 vector and treated with RC for 8d. DsRed2
+ cells were
sorted, and unsorted (RC) and sorted cells were analyzed. A: qPCR
analysis of beta-cell transcripts. Values are mean6SE, relative to human
islets (n=3 donors) and normalized to human RPLPO. B: Human C-
peptide content of fresh human islets and DsRed2-sorted RC-treated
islet cells. Values are mean6SE (n=3 donors). Note that most of the
insulin stored is processed (only 9% proinsulin). C: Glucose-induced
insulin secretion from human islets and RC-treated expanded islet cells
in the presence of 16.7 mM glucose and IBMX. Values are mean6SD of
human C-peptide, relative to 0 mM glucose and IBMX (n=3 donors). D:
Electron microscopic analysis reveals the presence of typical insulin
secretory vesicles in cells at p6 treated with RC for 8d, comparable to
those seen in beta cells in isolated human islets. Bar=0.5 mm.
doi:10.1371/journal.pone.0025566.g003
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e25566Figure 4. BCD cell redifferentiation involves MET. A,B: Induction of SLUG expression during islet cell dedifferentiation. A: qPCR analysis of
expanded islet cells at the indicated passages. Values are mean6SE relative to uncultured islets (n=4 donors) and normalized to human RPLPO.
*p,0.05. B: Immunoblotting analysis of protein extracted from uncultured islets and expanded islet cells at the indicated passage number. HSC70,
heat-shock cognate 70. C: Downregulation of SLUG expression during islet cell redifferentiation. qPCR analysis of expanded islet cells at p6–7
following 8d treatment with RC. Values are mean6SE relative to untreated cells (n=4 donors) and normalized to human RPLPO. *p,0.05. D: qPCR
analysis of kinetics of changes in NCAD and ECAD transcripts in expanded islet cells at p5 during 8d treatment with RC. Values are mean6SE
(logarithmic scale for ECAD) relative to untreated cells (n=4 donors) and normalized to human RPLPO or GAPDH. *p,0.05; **p,0.01. E:
Immunostaining analysis of expanded islet cells at p6 following 8d treatment with RC shows a decrease in the number of vimentin-positive cells
(mean6SD, based on counting .400 cells from each of 3 donors), and mutually-exclusive expression of vimentin and C-peptide. Arrow points to a
cell that may have already lost vimentin expression but has not activated yet insulin expression. Bar=10 mm. F: Co-staining for C-peptide and BrdU in
expanded islet cells at p5 following 8d treatment with RC. Percentages indicate the fraction of cells positive for BrdU among total cells, following
BrdU incorporation in days 2–8 of the redifferentiation treatment. Data are mean6SD, based on counting 500 cells from each of 3 donors.
Bar=20 mm. G: Immunoblotting analysis of expanded islet cells at p5 transduced with lentiviruses expressing one of two SLUG shRNAs or a
scrambled (SCR) shRNA. UTR, untreated cells. H: qPCR analysis of beta-cell transcripts in expanded islet cells at p5 transduced with lentiviruses
expressing one of two SLUG shRNAs or a scrambled shRNA and treated with RC for 4 days. Values are mean6SE relative to untreated cells (n=3–6
donors) and normalized to human RPLPO or GAPDH. *p,0.05, relative to SCR. UI, uninfected cells treated with RC.
doi:10.1371/journal.pone.0025566.g004
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SOX9 transcript levels were stimulated 5-fold by SLUG shRNA
(Figure 5E), suggesting that SOX9 expression is downstream of
MET. CK19- or amylase-positive cells could not be detected
following RC treatment (data not shown), suggesting that the
expanded islet cells did not give rise to duct- or acinar-like cells.
Expression of NGN3, a marker of islet progenitor cells, could not
be reproducibly detected by qPCR during redifferentiation.
Figure 5. BCD cell redifferentiation involves expression of pancreas- and islet-progenitor transcription factors SOX9 and NGN3,
respectively. A: RC treatment of expanded islet cells (p6) results in generation of hormone-expressing cells other than insulin. Cells were treated
with RC for 8 days and stained with antibodies for the indicated hormones (insulin-producing cells were identified by staining for C-peptide). Values
are mean6SE (n=4 donors), based on counting .500 cells from each donor. The inset pie-chart depicts the percent of cells positive for each
hormone among a total of 1736 hormone-positive eGFP
+ cells scored in parallel experiments with lineage-traced cells from 6 donors. B–D: SOX9
activation during redifferentiation. Islet cells at p5 were treated with RC for 8 days. B: qPCR analysis of kinetics of upregulation of SOX9. Values are
mean6SE, relative to untreated cells (d0) (n=4 donors), and normalized to human RPLPO or GAPDH. *p,0.05. C: Quantitation of SOX9
+ cells by
immunofluorescence analysis. Values are mean6SD, based on counting .500 cells from each of 3 donors at each time point. **p#0.01, ***p#0.001,
relative to untreated cells (d0). D: Left, Immunofluorescence analysis detects cells stained for vimentin or SOX9 alone, as well as double-positive cells.
Right, C-peptide and SOX9 staining is mutually exclusive. Bar=10 mm. E: qPCR analysis of SOX9 transcripts in expanded islet cells at p5 transduced
with lentiviruses expressing one of two SLUG shRNAs or a scrambled shRNA and treated with RC for 4 days. Values are mean6SE relative to untreated
cells (n=4–6 donors) and normalized to human RPLPO or GAPDH. UI, uninfected cells treated with RC. F: NGN3 is activated during redifferentiation.
In-situ hybridization analysis of NGN3 mRNA expression in human fetal pancreas cells (left panel) and expanded islet cells at p5 following 8d
treatment with RC treated islet cells (right panel). Bar=25 mm. G–H: Transient activation of SOX9 during islet cell dedifferentiation. G: qPCR analysis
of expanded islet cells at the indicated passages. Values are mean6SE relative to uncultured islets (n=3 donors) and normalized to human RPLPO.
*p,0.05. H: Immunoblotting analysis of protein extracted from uncultured islets and expanded islet cells at the indicated passage number.
doi:10.1371/journal.pone.0025566.g005
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INSM1 (Figure S4), a direct target of NGN3 [24]. RNA in-situ
hybridization revealed rare NGN3
+ cells on day 2 of the RC
treatment, and increasing numbers on days 4, 6, and 8 (Figure 5F),
suggesting a transition through a NGN3
+ stage during BCD cell
redifferentiation. No NGN3
+ cells were detected in expanded islet
cells untreated with RC (Figure 5F). Taken together, these findings
suggest that BCD cell redifferentiation proceeds through an islet-
progenitor-like stage, which may allow a low rate of differentiation
into other islet cell types, in addition to insulin-producing cells, in
particular the developmentally-related SST
+ cells. We also
detected transient SOX9 activation during the adaptation of
primary islet cells to proliferation in culture (Figure 5G,H),
suggesting that cell dedifferentiation also transits through a
progenitor-like stage.
Discussion
Our results present an approach for expansion of insulin-
producing cells from adult human islets in two stages, the first
involving expansion of the mixed islet cell population, including
,45% BCD cells, for up to 16 population doublings, followed by a
second stage of specific redifferentiation of BCD cells within the
expanded islet cell population (Figure 6). RC treatment achieved a
remarkably reproducible differentiation in cells from all human
donors tested. These conditions induced a profound phenotypic
change in the expanded cells, involving activation and shut-off of
multiple genes. Lineage tracing suggests that the predominant
source of newly-generated insulin-producing cells in these cultures
is redifferentiation of BCD cells. These findings demonstrate for
the first time that expanded dedifferentiated beta cells can be
induced to redifferentiate in culture. Although we can not exclude
a small contribution of other cell types to the C-pep
+ cells
generated by RC treatment, the percent of label-positive cells
among C-pep
+ cells is within the range of labelling efficiency,
supporting the likelihood that the bulk of differentiation represents
BCD cell redifferentiation. The mixed islet cell cultures may
contain cells expanded from MSCs originally present in the islet
preparation [25]; however we could not induce insulin expression
with RC in non-BCD mesenchymal cell types, such as fibroblasts
or BM-MSCs. The specific redifferentiation capacity of BCD cells
may be explained by a permissive epigenetic state (‘‘epigenetic
memory’’). Thus, beta-cell genes may be poised for expression,
however their lack of transcription may reflect an abnormal
balance between transcription activators and repressors, and/or
other chromatin modifications. Culture conditions in the rediffer-
entiation medium may restore the proper balance without
requirement for extensive epigenetic modifications.
Upon transfer to RC, BCD cells are depleted of growth factors
present in the serum of the expansion medium, resulting in growth
arrest. However, growth arrest by itself is not sufficient for
induction of redifferentiation in expanded islet cells, as suggested
by overexpression of the cell cycle inhibitor p57, which induced
growth arrest without differentiation (Bar et al., unpublished
results). The absence of serum also stimulates cell aggregation into
islet-like clusters, which likely contributes to formation of cell
conformation and cell-to-cell contacts required for BCD cell
redifferentiation. We previously observed that proliferation of
sorted BCD cells depended on factors secreted by non-BCD cells
in the islet cell culture [11]. It is possible that other cell types
Figure 6. Scheme of beta-cell expansion and redifferentiation. Human islet preparations are dissociated into single cells and cultured in
growth medium. Beta-cell dissociation from epithelial structure, and exposure to growth factors, induce EMT and dedifferentiation, but BCD cells
maintain epigenetic memory. All cell types in the mixed islet cell culture, of which ,45% are BCD cells, are induced to replicate. Following exposure
to RC treatment, ,25% of BCD cells undergo redifferentiation, which is associated with MET and activation of SOX9 and NGN3 expression. De-novo
differentiation of non-BCD cells does not contribute significantly to generation of insulin-producing cells.
doi:10.1371/journal.pone.0025566.g006
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secreted factors) needed for redifferentiation of BCD cells.
Redifferentiation of purified BCD cells, in the absence of non-
BCD cells, will help address this possibility.
BCD cell redifferentiation involves MET, as judged by changes
in gene expression, and by stimulation of redifferentiation upon
inhibition of the EMT effector SLUG. The mechanistic
correlation between MET and redifferentiation remains to be
elucidated. It is possible that restoration of ECAD expression
reinstates the normal cell-to-cell contacts needed for activation of
beta-cell genes. Alternatively, transcription factors involved in
EMT may act as repressors of beta-cell gene expression.
Treatment with RC induced redifferentiation of up to 25% of
all BCD cells at p5–7. This represents a net 8–32 fold increase in
the number of insulin-producing cells, compared to uncultured
islets. Improved redifferentiation conditions may extend the
redifferentiation capacity to later passages, and increase the
fraction of BCD cells undergoing redifferentiation, thus allowing
generation of a larger mass of insulin-producing cells. High-
throughput screening of compound libraries may identify agents
which can further stimulate redifferentiation of the expanded BCD
cells. Improved redifferentiation protocols, followed by sorting of
the insulin-producing cells generated, will allow functional
analyses in vivo, in immunodeficient mice. In addition to
improving the redifferentiation protocol, extension of the expan-
sion capacity beyond the ,16 population doublings obtained in
our current expansion conditions may be of potential value for
generation of higher numbers of insulin-producing cells.
Generation of SST
+ cells from lineage-traced cells suggests that
redifferentiation involves BCD cell transition through an islet
progenitor-like stage. Activation of expression of transcription
factors characteristic of islet progenitor cells during redifferentia-
tion, including SOX9, FOXA2, PDX1, NGN3, PAX4, and ARX,
supports this possibility. Nevertheless, the predominant hormone-
producing cell type generated from BCD cells by RC treatment is
insulin-positive cells (91.8%), followed by SST
+ cells (6.5%), and a
small fraction of GCG
+ and PPY
+ cells (1.2% and 0.5%,
respectively). It is intriguing to speculate that the epigenetic
memory directs these transitory islet progenitor-like cells back into
their cell type of origin, with some ‘‘leakage’’ into the
developmentally-related SST
+ cells. This culture system may
provide an attractive model of human islet progenitor cell
development, in which the cascade of transcription factor
activation elucidated from mouse gene knockout models can be
verified. Lineage tracing using progenitor cell gene promoters to
drive Cre expression will be required to prove the transition
through a progenitor-like stage during redifferentiation.
A recent paper presented evidence for expression of insulin in
rare human pancreas multipotent stem cells [26]. These findings
raise the possibility that our lineage tracing system labels these
cells, in addition to bona-fide beta cells, and therefore the
generation of insulin-positive cells observed in this study could be
attributed to de-novo differentiation of such stem cells, rather than
to redifferentiation. While we can not exclude contribution of
these cells, they are unlikely to be the major source of the
hormone-expressing cells generated in our differentiation culture
conditions. Our previous work documented a widespread
proliferation of eGFP
+ cells starting during the early days of islet
cell culture [11], which is inconsistent with expansion of a rare cell
type. In addition, a multipotent pancreatic stem cell would be
expected to give rise to all pancreatic cell types, including duct and
acinar cells, which could not be detected following RC treatment.
Thus, rather than reflecting expansion of rare pancreas multip-
otent stem cells, our data is consistent with transition of
redifferentiation through an islet progenitor-like stage, suggesting
that redifferentiation may recapitulate some aspects of islet
development.
Our findings suggest that ex-vivo expansion of adult human islet
cells is a promising approach for generation of insulin-producing
cells for transplantation, as well as research, toxicology studies, and
drug screening.
Supporting Information
Figure S1 Specificity of RIP-CreER transgene expres-
sion in beta cells. Human islet cells were transduced with the
RIP-CreER lentivirus vector and co-stained for Cre protein and
the 4 pancreatic islet hormones 2–3 d post infection (insulin
+ cells
were identified by staining for C-peptide). Values are mean6SD
(n=3 donors; based on counting 400 cells from each donor).
(TIF)
Figure S2 Islet cell differentiation decreases with cell
passaging. Insulin transcript levels in isolated islets, expanded
islet cells, and redifferentiated cells at the indicated passages, were
quantified by qPCR analysis. Results are mean6SE relative to
uncultured islets and normalized to human RPLPO (n=3–6
donors).
(TIF)
Figure S3 Kinetics of upregulation of islet progenitor
cell genes during RC treatment. qPCR analysis of expanded
islet cells at p5 treated with RC for the indicated number of days.
Values are mean6SE, relative to untreated cells (d0) (n=4
donors), and normalized to human GAPDH, *p,0.05, **p#0.01,
***p#0.001.
(TIF)
Figure S4 Upregulation of INSM1 following RC treat-
ment. qPCR analysis of INSM1 transcripts in expanded islet cells
at p5 following 8d treatment with RC. Values are mean6SE
relative to untreated cells (n=4 donors) and normalized to human
RPLPO.
(TIF)
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